cevimeline hydrochloride

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Head and Neck Cancer

Conditions

Head and Neck Cancer, Oral Complications, Radiation Toxicity

Trial Timeline

Jun 1, 2001 โ†’ Mar 1, 2003

About cevimeline hydrochloride

cevimeline hydrochloride is a phase 3 stage product being developed by Daiichi Sankyo for Head and Neck Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00017511. Target conditions include Head and Neck Cancer, Oral Complications, Radiation Toxicity.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00017511Phase 3Completed